

5-12-2021

## Nutritional status and eating habits of people who use drugs and/or are undergoing treatment for recovery: a narrative review

Nadine Mahboub  
*Lebanese International University*

Rana Rizk  
*Université Libanaise*

Mirey Karavetian  
*Zayed University*

Nanne de Vries  
*Maastricht University*

Follow this and additional works at: <https://zuscholars.zu.ac.ae/works>



Part of the [Medicine and Health Sciences Commons](#)

---

### Recommended Citation

Mahboub, Nadine; Rizk, Rana; Karavetian, Mirey; and de Vries, Nanne, "Nutritional status and eating habits of people who use drugs and/or are undergoing treatment for recovery: a narrative review" (2021). *All Works*. 4265.

<https://zuscholars.zu.ac.ae/works/4265>

This Article is brought to you for free and open access by ZU Scholars. It has been accepted for inclusion in All Works by an authorized administrator of ZU Scholars. For more information, please contact [Yrjo.Lappalainen@zu.ac.ae](mailto:Yrjo.Lappalainen@zu.ac.ae), [nikesh.narayanan@zu.ac.ae](mailto:nikesh.narayanan@zu.ac.ae).

# Nutritional status and eating habits of people who use drugs and/or are undergoing treatment for recovery: a narrative review

Nadine Mahboub, Rana Rizk, Mirey Karavetian, and Nanne de Vries

*A comprehensive overview is presented of the nutritional issues faced by people who use drugs or are undergoing treatment for recovery. Chronic substance use affects a person's nutritional status and body composition through decreased intake, nutrient absorption, and dysregulation of hormones that alter the mechanisms of satiety and food intake. Anthropometrics alone is not the best indicator of nutritional status, because this population has hidden deficiencies and disturbed metabolic parameters. Socioeconomic factors (eg, higher education, higher income, presence of a partner, living at home) positively affect nutritional status. Scarce available data on users undergoing treatment indicate improvement in anthropometric and metabolic parameters but with micronutrient intake remaining suboptimal. Weight gain is noted especially among women who use drugs and potentially increases their risk of relapse. Finally, specific amino acids and omega-3 fatty acids are promising in decreasing relapse and improving mental health during treatment; however, additional high-quality studies are needed. Nutrition intervention for people who use drugs or are undergoing treatment for recovery is underused; comprehensive programs addressing this population's unique needs are necessary. Future research will identify which components are needed.*

## INTRODUCTION

Nearly 5% of the world population is currently estimated to use drugs once daily, and almost 0.6% suffer from severe drug use disorder.<sup>1</sup> To date, opioids are the most harmful type of used drugs, and cannabis remains the world's most widely used drug.<sup>1</sup>

There are various types of treatments for drug addiction, including detoxification (complete abstinence) or opioid substitution treatment (OST).<sup>2</sup> Drug detoxification mostly takes place initially in hospitals, followed by psychotherapy and behavioral modification in a therapeutic community or a rehabilitation center.<sup>3</sup> By contrast, OST is a medication-assisted program during

Affiliation: *N. Mahboub* is with the Department of Nutrition and Food Sciences, Lebanese International University, Beirut, Lebanon, and Department of Health Promotion, Maastricht University, Maastricht, The Netherlands. *R. Rizk* is with the Institut National de Santé Publique, d'Epidémiologie Clinique et de Toxicologie, The Lebanese University, Beirut, Lebanon, and Department of Health Services Research, Maastricht University, Maastricht, The Netherlands. *M. Karavetian* is with the College of Natural and Health Sciences, Zayed University, Dubai, United Arab Emirates. *N. de Vries* is with the Department of Health Promotion, Maastricht University, Maastricht, The Netherlands.

Correspondence: *N. Mahboub*, Lebanese International University, P.O. Box 146404 Mazraa, Beirut, Lebanon. E-mail: nadine.mahboub@outlook.com.

*Key words:* drug users, health promotion, nutritional status, substance abuse treatment centers, substance-related disorders

©The Author(s) 2020. Published by Oxford University Press on behalf of the International Life Sciences Institute.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

which the patient receives a long-term opioid agonist (methadone or buprenorphine) to reduce the withdrawal symptoms and decrease the cravings for street opioids.<sup>4</sup> OST is suggested to be the more efficient method for reducing blood-borne illnesses like infection with the human immunodeficiency virus (HIV) and hepatitis.<sup>5</sup>

Drug use poses a cluster of harmful consequences to a person's well-being on psychological, emotional, and social levels.<sup>6</sup> It leads to increased risk of infectious illnesses<sup>7</sup> and medical issues, including mental disorders, cancer, stroke, and liver, lung, and cardiovascular diseases.<sup>8</sup>

Additionally, substance use can compromise the user's nutrition<sup>2</sup> and greatly affects their dietary habits. In general, this population has a disrupted and chaotic lifestyle, and money is usually spent on drugs rather than on food. This severely affects the user's food intake, which eventually leads to undernutrition.<sup>9</sup> Other factors affecting the nutritional status of drug users include the type, frequency, and duration of the drug used and the presence of infectious diseases.<sup>10</sup> Furthermore, the type of treatment drug users might be receiving, such as being enrolled in a detoxification program and living in a rehabilitation center vs receiving OST and living in the community, might also influence their nutritional status.<sup>11</sup>

In this article, the literature on the nutritional issues faced by people who use drugs (PWUD) or those undergoing treatment for recovery is reviewed, as is the effect of drug use on dietary intake and dietary habits. The effect of drugs on anthropometric indices, body composition, nutrient deficiencies, and metabolic parameters are exposed, and the effect of nutrition on substance use and the changes that occur during treatment and recovery are discussed. The term *malnutrition* describes a state of imbalance—excess or deficiency—that leads to alteration in body composition and negatively affects the health status of the individual. In this article, the term *malnutrition* is used synonymously with *undernutrition*.

We chose to conduct a narrative review because there are many different topics in this field with few studies on each and statistical combination is impossible. These data will be compiled to have a comprehensive overview and provide new insights on drug users' eating patterns for future nutritional interventions in the promotion of good health among this population.

Various databases were searched for relevant literature (namely, PubMed, Google Scholar, Science Direct, and Medline), using the following terms: “nutrition” OR “nutritional status” OR “malnutrition” OR “dietary habits” AND “illicit drug use” OR “substance abuse” OR “drug use\*” OR “drug treatment.” The keywords

were modified according to the searched database. In addition, references of included articles were reviewed for inclusion when we thought they were relevant. Searches were restricted to English-language journals and a date range of 1990 until the present. A total of 83 studies initially were included in the review. Eight additional studies were suggested by key scholars; accordingly, the total number of studies included was 91.

### **Effect of drug use on dietary habits: food preferences, eating behaviors, and appetite regulation**

Little research has been done to tackle the issues of food preferences and dietary habits of active drug users or those undergoing different treatment modalities. Cocaine drug users have irregular eating patterns and rely mainly on 1 meal taken late at night. Typically, this meal is high in refined carbohydrates and fat and low in fruits and vegetables.<sup>12–14</sup> People addicted to opiates replace protein and fats with meals high in sugar and alcohol, which are low in essential nutrients and, therefore, are sources of empty calories.<sup>9</sup> Substantial evidence supports the increased preferences for sweet taste among PWUD.<sup>15–20</sup>

During the early phase of detoxification, when patients are still receiving pharmacotherapy, they report a period of low food intake, and eating becomes their last priority as they experience nausea, anorexia, and gastrointestinal disturbances, all of which make eating difficult.<sup>12,19</sup> Between the first and sixth month of detoxification, a high preference and craving for table sugar and sweet foods, such as cakes and confectionary foods, often takes place as a replacement for the drug. However, in the later recovery phase, after 6 months, sugar cravings seem to level off with more structural food intake and improved appetite.<sup>17,19,21</sup>

Studies of persons receiving OST also show higher preference and intake of sugary foods<sup>15,22–24</sup> (eg, high consumption of table sugar, yogurt, and soft drinks), with very little intake of fruits and vegetables.<sup>25,26</sup> Sugary foods appear to be the preferred foods for PWUD or those undergoing treatment. This preference may be an indication of addictive tendencies, because some studies show that heroin users have these cravings prior to using heroin more than after using it.<sup>27</sup>

The poor dietary habits decreasing food intake, the preference for sugary foods contributing to empty calories, the compromised liver storage and/or increased excretion of nutrients with accompanying diseases like HIV and hepatitis are major risk factors for malnutrition and hazardous health among PWUD.<sup>28</sup>

Nutrition knowledge seems to affect dietary choices in this population. For instance, when nutrition knowledge was offered as part of an OST program, sugary

food craving was still observed but healthier foods and more meals were consumed by the participants.<sup>18</sup>

### **Effect of drug use on dietary intake: macro- and micronutrients**

In the short term, opiates cause anorexia, decreased food consumption, and reduced gastrointestinal motility, all leading to malnutrition and increased risk of infections in the long term.<sup>29</sup> Socioeconomic factors like education and income are positively associated with nutritional indices like body mass index (BMI), hemoglobin level, and serum protein levels among PWUD. This association is in agreement with the well-documented fact that socioeconomic factors are related to the nutritional status of the individual, in addition to the high prevalence of self-reported homelessness among PWUD.<sup>20,30</sup> Similarly, people who use heroin and cocaine have lower energy and protein intake than nonusers.<sup>16,31</sup> This intake seems to decline more with higher intensity and duration of drug use.<sup>10</sup> The presence of disease also appears to affect food intake. HIV-positive PWUD have more energy, protein, and fat-deficient diets compared with PWUD who are HIV negative.<sup>28</sup> The high levels of food insecurity among this population are mainly due to the limited funds, which are usually allocated to the support of their habits rather than food; this leads to serious decrease in intake levels.

Consistent with the lower intakes of nutrient-dense foods in this population, the intake of the majority of vitamins and minerals, like thiamin, riboflavin, pyridoxine, folate, vitamin D, vitamin C, magnesium, iron, calcium, zinc, copper, and selenium is below the recommended intake.<sup>32</sup> The nutritional imbalance (a higher ratio of macronutrients to micronutrients) indicating higher intakes of empty calories is strongly associated with drug use.<sup>33</sup>

### **Effect of drug use on plasma nutrient deficiencies**

The malnutrition of PWUD, assessed by anthropometric measurements, is not usually very severe; thus, measuring the plasma levels of macronutrients and micronutrients might reveal hidden deficiencies that reflect the decrease in the intake of these nutrients.

Essential nutrients are depleted among PWUD in general.<sup>15</sup> This population exhibits low selenium and potassium levels due to lower muscle mass attributed to malnutrition.<sup>34</sup> Iron deficiency and iron-deficiency anemia are widespread, mostly among female PWUD,<sup>35–37</sup> as are low plasma levels of vitamins A, C, D, and E. The latter is inversely correlated with the dose and period of addiction.<sup>16,30,35</sup> These deficiencies are mainly caused

by restricted access to foods, in addition to the food choices previously discussed.<sup>16,30,35</sup> Thus, the issue of vitamin and mineral supplementation among PWUD and during treatment requires additional consideration.

On the other hand, the plasma levels of some minerals are reported to be higher in this group compared with healthy individuals. This is not due to proper nutrition but rather is attributed to factors unique to PWUD. Higher serum levels of phosphorus, sodium, and magnesium are tentatively attributed to partial dehydration.<sup>15</sup> Similarly, increased serum levels of copper and zinc are due to inflammation, acute fasting, and smoking.<sup>15,34,36</sup>

### **Effect of drug use on anthropometric indices and body composition**

Although scarce, the majority of the literature assessing the nutritional status of PWUD mostly points toward malnutrition.<sup>11</sup> The relation among drug use, body weight, and BMI has been addressed in many epidemiological studies, and most of the evidence shows an inverse correlation among these variables.<sup>28,38</sup> On admission for detoxification, up to 70% of PWUD have BMI values below the normal range or weight values below the population mean.<sup>10</sup> Similarly, Ross et al<sup>35</sup> showed that 24% of PWUD, within a short period of admission for detoxification, exhibited mild to moderate malnutrition, based on the Subjective Global Assessment.

In general, the BMI of PWUD is lower than that of nonusers. HIV-positive persons who use cocaine have the lowest BMI, as compared with users of other drugs or with nonusers.<sup>39</sup> It is believed that cocaine suppresses appetite and decreases food intake, and subsequently body weight, by inhibiting dopamine transporters, decreasing reuptake of serotonin, upregulating the glucocorticoid production, and increasing the cocaine- and amphetamine-regulated transcript expression.<sup>40,41</sup> Cowan et al<sup>21</sup> supported this finding when reporting that weight was gained with the cessation of cocaine use. Ersche et al<sup>13</sup> challenged the assumption that cocaine leads to weight loss through appetite suppression; rather, they suggested that metabolic alteration is the cause. Their findings showed that cocaine users had lower body weight and fat mass as compared with nonusers, despite reporting higher dietary fat and carbohydrate intake.

People who smoke heroin appear to have a lower BMI and body weight than nonusers. This inverse correlation is modulated by the high frequency (>3 times/d) and the route of administration of the drug.<sup>38</sup> The significant negative contribution of smoked heroin to body weight and BMI may be due to faster rate of brain

**Table 1 Factors contributing to lower body weight, BMI, and body composition among drug users**

Factor	Finding
Sex	Underweight is more frequent among women than men.
Type of drug	Heroin: highest percentage of drug users in underweight category Cocaine: decrease in weight specific to fat mass with no significant changes in BMI Amphetamines: higher risk of obesity in users as compared with morphine users Methylamphetamines: lower BMI as compared with nonusers
Frequency and route of administration	Multiple drug use for a long duration is negatively associated with the nutritional status. Smoking has faster delivery of the drug to the brain, resulting in a lower BMI as compared with snorting or injection.
Food insecurity and poverty	Negative effect on the nutritional status by decreasing body weight, body fat, and BMI
Pathological diseases	Add to the severity of malnutrition among drug users
Treatment	Healthier dietary habits seen in detoxification and OST

Abbreviations: BMI, body mass index; OST, opioid substitution treatment.

delivery of the drug as compared with injection, snorting, or oral ingestion, leading to greater reinforcing effects. Substances like heroin may compete with food in the brain activating reward pathways and increasing dopamine receptor<sup>7</sup> availability, thus suppressing the appetite and leading to lower body weight. This is particularly noted among heroin smokers.<sup>38,42–45</sup>

McIlwraith et al<sup>46</sup> showed that heroin users are more prone to being underweight as compared with morphine and amphetamine users, whereas people who use amphetamines were at higher risk of being obese as compared with morphine users. This finding is contradictory to the appetite-suppressing effect of amphetamine, and its relevance to the general population will need to be investigated by future studies, because this increase in obesity was found only in comparison with morphine users and not with a nondrug-using control group.<sup>46,47</sup>

Methylamphetamine (MA), a relatively new psychostimulant (the second most widely used drug now after heroin, marijuana, and others) is associated with cardiac and hepatic pathology, neurological impairment, mood disorders, and malnutrition.<sup>48</sup> People dependent on MA have a lower BMI as compared with that of healthy individuals. This might be due to cognitive deficits, abnormal metabolic activity, duration of MA use, and improper oral health that affects food chewing and, thus, intake.<sup>48,49</sup> More frequent use of other types of drugs such as marijuana or sedatives showed a weak association with a lower BMI, although this association is statistically not significant.<sup>39,50</sup>

In addition, sex might influence the BMI, weight, and body composition of PWUD. Women who are heavy drug users (ie, using methadone or injection of drugs >16 times/wk) have less body fat and lower BMI as compared with PWUD moderately or infrequently, and nonusers. This difference among different levels of drug use is not present in men.<sup>51</sup> This study by "Cofrancesco et al.<sup>51</sup>" confirms the results of studies that showed a negative relation between drug use and BMI solely among women and not men.<sup>10,52,53</sup>

Furthermore, factors like decreased frequency of food consumption are negatively associated with body weight and BMI. Also, poverty resulting from unemployment, common among PWUD, leads to an inability to purchase nutritious foods and is associated with a low BMI. In addition, multiple drug use can lead to poorer nutritional status due to the appetite-suppressing effect of the drug.<sup>20,28,30</sup>

Interestingly, Richardson et al<sup>54</sup> showed that BMI alone may not be the best indicator to assess PWUD because there was no association between BMI and the nutritional risk level of PWUD when screened. Using other tools to assess appetite, diet quality, and biochemical parameters better identified nutritional deficiencies to be addressed.<sup>35</sup>

Throughout treatment processes, whether by OST or detoxification, PWUD start to consume healthier foods and more structured meals.<sup>19,21,26</sup> Better dietary habits are seen among those in residential homes where meals are provided, or later in recovery when food preparation becomes a more sociable and satisfying activity as compared with PWUD who have severe addiction and for whom eating is given little consideration.<sup>19</sup> Table 1 summarizes the factors contributing to changes in anthropometric indices and body composition among PWUD.

### Effect of drug use on plasma metabolic parameters

The effect of drug use on plasma parameters has also been studied with emphasis on lipid profile, glucose and hemoglobin levels, and hematocrit. In general, plasma total cholesterol has an inverse relation with drug use. Persons addicted to opium, heroin, and MA have a significant decrease in serum cholesterol level as compared with nonusers but with no change in triglyceride levels.<sup>49,55–58</sup> By contrast, comparing HIV-positive and HIV-negative injecting drug users with a control group, total cholesterol levels were lower and triglyceride levels were significantly higher in the HIV-positive drug users, indicating the possible effect of the disease

itself and not the drug use.<sup>28</sup> These findings were supported by Maccari et al,<sup>59</sup> who found that heroin users had significantly lower serum cholesterol and high-density lipoprotein levels, and higher triglyceride levels than nonusers. The aforementioned decrease in serum lipid levels could be mainly attributed to malnutrition and weight loss, specifically the loss of abdominal fat, in addition to the presence of liver diseases or HIV that are common among heroin users.

Decreased plasma cholesterol levels have been associated with many negative psychological behaviors, including aggression, depression, and suicide<sup>60</sup>; however, this remains controversial. Low plasma cholesterol levels can alter tissue concentration of polyunsaturated fatty acids, the depletion of which has important consequences on modulating the serotonergic and dopaminergic functions that play key roles in the aforementioned behaviors. Yet, to date, a causal relationship has not been shown.<sup>58,61–63</sup> Persons addicted to cocaine who relapsed after detoxification had lower plasma cholesterol values (<160 mg/dL) than those who did not, suggesting an increased vulnerability to the development of behavioral and psychological disorders with low cholesterol levels.<sup>55</sup> Whether these diminished levels are associated with drug craving still needs to be investigated.

Glucose is another parameter that was studied in PWUD and remains not well understood. In a study by Zhang et al,<sup>48</sup> the fasting blood glucose levels of persons addicted to MA were lower than those of control participants. This finding runs in parallel with studies done on animals that reported a direct effect of MA on the pancreas, leading to insulin secretion and induced hypoglycemia.<sup>64</sup> On the other hand, non-insulin dependent persons with diabetes who used opium had higher glycosylated hemoglobin values than did nonusers, thereby indicating elevated blood glucose levels in the former for the previous 3 months.<sup>65</sup> The effect of morphine on glucose has been demonstrated in animals, with several mechanisms suggested, like an increase in hormone levels including adrenalin, noradrenalin, corticosterone, and glucagon; these, in turn, increase blood glucose levels.<sup>66,67</sup> Among the very few studies on humans, Carey et al<sup>68</sup> showed that morphine can induce a reduction in the plasma counterregulatory epinephrine response, thus causing hypoglycemia symptoms in healthy individuals without diabetes. More studies are needed to confirm if behavioral factors play a role in the effect of drugs on plasma glucose levels.

Hemoglobin and hematocrit levels are lower in PWUD than in nonusers, with the lowest levels seen among multiple-drug users and those with longer duration of addiction.<sup>30</sup> This finding was related to

malnutrition and decreased micronutrient intakes, especially iron.<sup>69</sup> The decrease in hemoglobin levels and hematocrit among PWUD is specifically noted among women. This might be because men are institutionalized for a longer period than women and that, in turn, correlates with better nutritional status.<sup>32,35</sup>

### Nutritional changes during recovery (detoxification or OST)

In addition to being an effective method for reducing harm, OST or methadone maintenance treatment (MMT) also improves the nutritional status of PWUD, whereby the BMI and weight of users starting treatment significantly increase.<sup>70,71</sup> The increased weight and BMI are mostly seen in patients with higher education and income, suggesting a positive role of social factors on the nutritional status of PWUD.<sup>20,30,70,72</sup> From the patients' point of view, MMT has a positive impact on their physical health, sleep, and weight gain.<sup>73</sup> They report better appetite, change in taste, and more desire to eat.

PWUD starting MMT show a decreased intake in the majority of the nutrients (ie, fats, cholesterol, fibers, and some minerals and vitamins) 2 months after beginning treatment, followed by an increase after 9 months.<sup>74</sup> Sex might modulate the effect of MMT on weight gain. Whereas studies show an increase in dietary intake, body weight, BMI, and skin fat folds among men, as compared with a modest weight loss in women,<sup>74</sup> other studies show the opposite, with women having a much greater increase in BMI and weight than men.<sup>75</sup> The reason underlying this significant difference between sexes does not seem to be related to the duration of the treatment and needs additional investigation. The increase in weight and BMI may not be due to the shift toward a healthier eating pattern but might be related to the pharmacological aspect of the treatment itself.<sup>23,75,76</sup> Detoxification also results in increased weight and food intake,<sup>77–79</sup> which vary at different recovery stages. In the early stages, binge eating is observed as a result of the replacement of drugs with food. Binging may be related to changes in the eating behaviors of PWUD after periods of food restriction caused by drugs. In later stages of their recovery, PWUD developed more structured and less frequent overeating habits.<sup>21</sup>

The studies regarding the effect of MMT on some metabolic parameters are limited. After 6 months of MMT, persons addicted to opioids show an increase in serum levels of leptin, total cholesterol, high-density lipoprotein, and low-density lipoprotein, compared with serum levels before initiation of the treatment.<sup>70,80</sup> A positive correlation has been shown between leptin,

**Table 2 Effect of drug use and treatment methods on the nutritional status**

	Drug use	OST	Detoxification
Food preferences	Consumption of 1 meal/d with higher preference for sugars and fats and lower intakes of fruits and vegetables	Better appetite and increased number of meals High consumption of sugars, yogurt, and soft drinks with low intakes of fruits and vegetables	Binging on sweets in early phases of treatment with more structured food intakes in later recovery stages
Macro- and micronutrient intake	Deficits in energy and protein Majority of vitamins and minerals below RI	Higher energy, proteins, and carbohydrates after initiation of treatments, with a decrease in later stages	Higher energy, proteins, and carbohydrates after initiation of treatments, with a decrease in later stages.
Plasma nutrients	Low levels of Se, K, Fe, vitamins A, D, C, and E High levels of Mg, Na, and Ph attributed to dehydration	Majority of micronutrient levels stayed below the recommended levels.	Majority of micronutrient levels stayed below the recommended levels.
Anthropometrics	Decrease in BMI and weight with variations based on the type of drug	Significant increase in BMI and weight, with more significance in women, placing them in the overweight category.	Increase in weight and food intake in early stages of recovery
Metabolic parameters	Low levels of total and HDL-cholesterol, leptin, FBS, Hct, and Hb	Increase in total and HDL-cholesterol and leptin levels	

*Abbreviations:* BMI, body mass index; FBS, fasting blood sugar; Fe, iron; Hb, hemoglobin; Hct, hematocrit; HDL, high-density lipoprotein; K, potassium; Mg, magnesium; Na, sodium; OST, opioid substitution treatment; Ph, phosphorus; RI, recommended intake; Se, selenium.

BMI, and serum lipid levels, with greater effect among women; this is attributed to the difference in percent body fat mass.

As for micro- and macronutrient intake during MMT or detoxification, an increase in the overall intake of energy, proteins, and carbohydrates occurs with both modalities after initiation of the treatment. Yet, this is followed by a decrease in later stages of recovery, when the food intake starts to become more structured. Interestingly, intake of the majority of the minerals remains below the recommended levels, especially in patients with HIV; this could be related to the increased intake of energy-dense foods rather than nutrient-dense ones.<sup>24,81</sup>

Personal and environmental factors like decreased physical activity and the purchase of high-fat, less-expensive foods play a role in the weight gain seen among patients in recovery from drug use, thereby highlighting the need to incorporate exercise and nutrition information as part of the treatment.<sup>82</sup> Exercise reduces stress, anxiety, depression, and drug use in individuals recovering from substance use.<sup>83</sup>

Better nutrition knowledge and healthier eating habits are seen among PWUD in MMT after receiving nutrition lectures as part of the treatment program, although no effect on BMI and weight gain is seen. This could be because the intervention program emphasized the healthier eating habits and did not specifically target weight reduction.<sup>84</sup>

Concerns about weight gain among women drug users in recovery is a potential risk factor for relapse. In

a study of 297 women of different ethnicities who were recruited from 7 different treatment facilities, Warren et al<sup>79</sup> reported that 70% were concerned about weight gain during recovery, and 45% were concerned about relapse because of this gain. One-third of the sample indicated that weight loss was a reason to initiate drug use to start with. Similarly, drug use was positively associated with overweight among female adolescents.<sup>85</sup> Data revealing drug users' perceptions about the kind of intervention programs for tackling the weight gain they face during treatment are scarce. Most of the research suggests similarities between women and men in terms of drug-use behaviors; however, significant differences exist that may indicate a need for more sex-specific research on prevention and treatment strategies.<sup>85</sup> On the basis of these findings, giving individualized behavioral recommendations must be considered, because all intervention research shows its efficiency. Table 2 summarizes the effect of drug use and treatment on different aspects of the nutritional status of PWUD.

### Effect of nutrition on substance use

The high prevalence of PWUD with mood disorders like depression and anxiety has been confirmed by numerous, large epidemiological studies<sup>86–88</sup> and these disorders, in turn, may have a negative impact on users' recovery, which will lead to relapse.<sup>15,89</sup> Essential micronutrients play an important role in mood regulation by the brain,<sup>33</sup> and deficiencies or insufficient intakes of these nutrients, in addition to food

deprivation, correlate with poor mental health, especially depression.<sup>90,91</sup> Serotonin plays a role in the modulation of many behaviors, including violence, aggression, mood, sleep, and appetite.<sup>92,93</sup> The synthesis of serotonin starts with the amino acid tryptophan. Increasing dietary intake of tryptophan can increase serotonin levels, thus modulating the aforementioned behaviors. Data in the literature concerning the positive effect of tryptophan supplementation on depression are inconsistent; consensus has not yet been reached regarding the effectiveness in the treatment of drug use.<sup>93–95</sup> Tyrosine and phenylalanine are also involved in the synthesis of dopamine and catecholamines that influence behavioral performance, with limited and inconsistent evidence that their supplementation is beneficial in the treatment of PWUD.<sup>15,95,96</sup> When patients dependent on heroin or opiates are given a combination of amino acids (namely, phenylalanine, tryptophan, tyrosine, and glutamine) while undergoing detoxification, they show a significant reduction in the craving for opiates.<sup>97</sup> This might be an important tool in the treatment of drug use that warrants additional study.

The provision of micronutrients is required as a cofactor for the synthesis of serotonin, dopamine, and catecholamines.<sup>98,99</sup> Deficiencies of copper, selenium, manganese, magnesium, folate, and B-complex vitamins are linked to depression,<sup>98,100–102</sup> which might hinder the treatment process of drug users. Vitamin and mineral supplementation should be considered, not only for the management of malnutrition but also as a preventive measure of relapse.

Furthermore, fatty acids are also involved in regulating the aforementioned behaviors.<sup>103,104</sup> Elevated levels of corticotropin-releasing hormone, which is associated with defensive and violent behaviors, decrease with supplementation of a combination of omega-3 fatty acid docosahexaenoic and eicosapentaenoic acids.<sup>105</sup> Patients undergoing detoxification from drug use have a decrease in anger score upon supplementation with docosahexaenoic acid, whereas lower anxiety scores are associated with supplementation with eicosapentaenoic acid.<sup>106</sup>

Supplementation could have a positive effect on the psychological behaviors that might prevent relapse. The intake of specific nutrients like amino acids and omega-3 fatty acids are promising in decreasing relapse and improving mental health during treatment, but additional high-quality studies are needed to provide evidence that such supplementation can increase the efficacy of the treatment of PWUD.

## CONCLUSION

PWUD are a vulnerable population, and most of the research exploring their nutritional status points to

malnutrition. Substance use affects the nutritional status and body composition through decreased food intake and nutrient absorption, altered metabolism, and use of multiple drugs, in addition to the dysregulation of hormones altering the mechanism of satiety and food intake. Anthropometric measurements alone are not the best indicators of assessment in this patient population, because active users and those seeking treatment have many hidden deficiencies and disturbed metabolic parameters. Socioeconomic factors like education, income, presence of a partner, and living in a residential home where meals are provided have a positive impact and should be considered.

Scarce available data indicate improvements in the anthropometric and metabolic parameters of PWUD when they initiate treatment, but micronutrient levels remain below recommended intake values. Yet, an increase in weight is noted, which might pose negative health implications.

All of these factors draw attention to the importance of proper, comprehensive nutrition care being provided for drug users and in treatment centers. Simple nutrition education about healthy eating habits improves the quality of the nutritional intake of PWUD but does not seem to be solely effective in treating the problems faced by users and those undergoing treatment and improving their outcomes. This indicates the need for an individualized and comprehensive nutritional intervention. The components of this intervention still need to be determined by future studies.

## Acknowledgments

*Author contributions.* N.M. did the literature search, collected and interpreted the data, and drafted the manuscript. R.R. interpreted the data, wrote original content, and critically revised the manuscript. M.K. and N.V. wrote original content and critically revised the manuscript. All authors approved the final version of the manuscript.

*Funding.* None

*Declaration of interest.* None

## REFERENCES

1. Merz F. United Nations Office on Drugs and Crime: World Drug Report; SIRIUSZeitschrift für *Strategische Analysen*. 2017;2:85–86.
2. Nabipour S, Ayu Said M, Hussain Habil M. Burden and nutritional deficiencies in opiate addiction: systematic review article. *Iran J Public Health*. 2014;43:1022–1032.
3. Gerstein DR, Lewin LS. Treating drug problems. *N Engl J Med*. 1990;323:844–848.



4. Rapeli P, Fabritius C, Alho H, et al. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. *BMC Clin Pharmacol*. 2007;7:5–5.
5. Caplehorn JR, Ross MW. Methadone maintenance and the likelihood of risky needle-sharing. *Int J Addict*. 1995;30:685–698.
6. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. *Lancet*. 2012;379:55–70.
7. Spronk DB, van Wel JH, Ramaekers JG, et al. Characterizing the cognitive effects of cocaine: a comprehensive review. *Neurosci Biobehav Rev*. 2013;37:1838–1859.
8. Volkow ND. *Drugs, Brains, and Behavior: The science of addiction*. NIDA National Institute of Drug Abuse. National Institute of Health US Department of Health and Human Services; 2010.
9. Morabia A, Fabre J, Ghee E, et al. Diet and opiate addiction: a quantitative assessment of the diet of non-institutionalized opiate addicts. *Br J Addict*. 1989;84:173–180.
10. Santolaria-Fernandez FJ, Gomez-Sirvent JL, Gonzalez-Reimers CE. Nutritional assessment of drug addicts. *Drug Alcohol Depend*. 1995;38:11–18.
11. Forrester JE, Tucker KL, Gorbach SL. The effect of drug abuse on body mass index in Hispanics with and without HIV infection. *Public Health Nutr*. 2005;8:61–68.
12. Noble C, McCombie L. Nutritional considerations in intravenous drug misusers: a review of the literature and current issues for dietitians. *J Hum Nutr Diet*. 1997;10:181–191.
13. Ersche KD, Stochl J, Woodward JM, et al. The skinny on cocaine: insights into eating behavior and body weight in cocaine-dependent men. *Appetite*. 2013;71:75–80.
14. Billing L, Ersche KD. Cocaine's appetite for fat and the consequences on body weight. *Am J Drug Alcohol Abuse*. 2015;41:115–118.
15. Jaynes KD, Gibson EL. The importance of nutrition in aiding recovery from substance use disorders: a review. *Drug Alcohol Depend*. 2017;179:229–239.
16. Sæland M, Haugen M, Eriksen FL, et al. High sugar consumption and poor nutrient intake among drug addicts in Oslo. *Br J Nutr*. 2011;105:618–624.
17. Stickel A, Rohdemann M, Landes T, et al. Changes in nutrition-related behaviors in alcohol-dependent patients after outpatient detoxification: the role of chocolate. *Subst Use Misuse*. 2016;51:545–552.
18. Nolan LJ, Scagnelli LM. Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. *Subst Use Misuse*. 2007;42:1555–1566.
19. Neale J, Nettleton S, Pickering L, et al. Eating patterns among heroin users: a qualitative study with implications for nutritional interventions. *Addiction*. 2012;107:635–641.
20. Himmelfgren DA, Perez-Escamilla R, Segura-Millan S, et al. A comparison of the nutritional status and food security of drug-using and non-drug-using Hispanic women in Hartford, Connecticut. *Am J Phys Anthropol*. 1998;107:351–361.
21. Cowan J, Devine C. Food, eating, and weight concerns of men in recovery from substance addiction. *Appetite*. 2008;50:33–42.
22. Peles E, Schreiber S, Sason A, et al. Risk factors for weight gain during methadone maintenance treatment. *Substance Abuse*. 2016;37:613–618.
23. Mysels DJ, Sullivan MA. The relationship between opioid and sugar intake: review of evidence and clinical applications. *J Opioid Manag*. 2010;6:445–452.
24. Kolarzyk EC, Maj J, Pach D, et al. Assessment of daily nutrition ratios of opiate-dependent persons before and after 4 years of methadone maintenance treatment. *Przegl Lek*. 2005;62:368–372.
25. Zador D, Lyons Wall PM, Webster I. High sugar intake in a group of women on methadone maintenance in south western Sydney, Australia. *Addiction*. 1996;91:1053–1061.
26. Bogucka-Bonikowska A, Baran-Furga H, Chmielewska K, et al. Taste function in methadone-maintained opioid-dependent men. *Drug Alcohol Depend*. 2002;68:113–117.
27. Levine AS, Kotz CM, Gosnell BA. Sugars and fats: the neurobiology of preference. *J Nutr*. 2003;133(suppl 3):831S–834S.
28. Tang AM, Bhatnagar T, Ramachandran R, et al. Malnutrition in a population of HIV-positive and HIV-negative drug users living in Chennai, South India. *Drug Alcohol Depend*. 2011;118:73–77.
29. White R. Drugs and nutrition: how side effects can influence nutritional intake. *Proc Nutr Soc*. 2010;69:558–564.
30. Nazrul Islam SK, Hossain KJ, Ahmed A, et al. Nutritional status of drug addicts undergoing detoxification: prevalence of malnutrition and influence of illicit drugs and lifestyle. *Br J Nutr*. 2002;88:507–513.
31. Forrester JE, Tucker KL, Gorbach SL. Dietary intake and body mass index in HIV-positive and HIV-negative drug abusers of Hispanic ethnicity. *Public Health Nutr*. 2004;7:863–870.
32. Sæland M, Haugen M, Eriksen F-L, et al. Living as a drug addict in Oslo, Norway: a study focusing on nutrition and health. *Public Health Nutr*. 2009;12:630–636.
33. Schroeder RD, Higgins GE. You are what you eat: the impact of nutrition on alcohol and drug use. *Subst Use Misuse*. 2017;52:10–24.
34. Diaz-Flores JF, Sañudo RI, Rodríguez EM, et al. Serum concentrations of macro and trace elements in heroin addicts of the Canary islands. *J Trace Elem Med Biol*. 2004;17:235–242.
35. Ross LJ, Wilson M, Banks M, et al. Prevalence of malnutrition and nutritional risk factors in patients undergoing alcohol and drug treatment. *Nutrition*. 2012;28:738–743.
36. Hossain KJ, Kamal MM, Ahsan M, et al. Serum antioxidant micromineral (Cu, Zn, Fe) status of drug dependent subjects: influence of illicit drugs and lifestyle. *Subst Abuse Treat Prev Policy*. 2007;2:12.
37. Semba RD, Shah N, Strathdee SA, et al. High prevalence of iron deficiency and anemia among female injection drug users with and without HIV infection. *J Acquir Immune Defic Syndr*. 2002;29:142–144.
38. Li J, Yang C, Davey-Rothwell M, et al. Associations between body weight status and substance use among African American women in Baltimore, Maryland: the CHAT Study. *Subst Use Misuse*. 2016;51:669–681.
39. Quach LA, Wanke CA, Schmid CH, et al. Drug use and other risk factors related to lower body mass index among HIV-infected individuals. *Drug Alcohol Depend*. 2008;95:30–36.
40. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. *Nature*. 2001;410:822–825.
41. Kuhar MJ. CART peptides and drugs of abuse: a review of recent progress. *J Drug Alcohol Res*. 2016;5:1–6.
42. Wiss DA. A biopsychosocial overview of the opioid crises: considering nutrition and gastrointestinal health. *Front Public Health*. 2019;7:1–52.
43. Volkow ND, Fowler JS, Wang GJ, Swanson JM, et al. Dopamine in drug abuse and addiction. *Arch Neurol*. 2007;64:1575–1579.
44. Trinko R, Sears RM, Guarnieri DJ, et al. Neural mechanisms underlying obesity and drug addiction. *Physiol Behav*. 2007;91:499–505.
45. Volkow ND. Stimulant medications: how to minimize their reinforcing effects? *Am J Psychiatry*. 2006;163:359–361.
46. McIlwraith F, Betts KS, Jenkinson R, et al. Is low BMI associated with specific drug use among injecting drug users? *Subst Use Misuse*. 2014;49:374–382.
47. Blüml V, Kapusta N, Vyssoki B, et al. Relationship between substance use and body mass index in young males. *Am J Addict*. 2012;21:72–77.
48. Lv D, Zhang M, Jin X, et al. The body mass index, blood pressure, and fasting blood glucose in patients with methamphetamine dependence. *Medicine*. 2016;95:e3152.
49. Zhang M, Lv D, Zhou W, et al. The levels of triglyceride and total cholesterol in methamphetamine dependence. *Medicine*. 2017;96:e6631.
50. Barry D, Petry NM. Associations between body mass index and substance use disorders differ by gender: results from the national epidemiologic survey on alcohol and related conditions. *Addict Behav*. 2009;34:51–60.
51. Cofrancesco J Jr, Brown TT, Luo RF, et al. Body composition, gender, and illicit drug use in an urban cohort. *Am J Drug Alcohol Abuse*. 2007;33:467–474.
52. Forrester JE, Woods MN, Knox TA, et al. Body composition and dietary intake in relation to drug abuse in a cohort of HIV-positive persons. *J Acquir Immune Defic Syndr*. 2000;25(suppl 1):S43–S48.
53. Karmon SL, Moore RD, Dobs AS, et al. Body shape and composition in HIV-infected women: an urban cohort. *HIV Med*. 2005;6:245–252.
54. Richardson RA, Wiest K. A preliminary study examining nutritional risk factors, body mass index, and treatment retention in opioid-dependent patients. *J Behav Health Serv Res*. 2015;42:401–408.
55. Buydens-Branchey L, Branchey M. Association between low plasma levels of cholesterol and relapse in cocaine addicts. *Psychosom Med*. 2003;65:86–91.
56. Kouros D, Tahereh H, Mohammadreza A, et al. Opium and heroin alter biochemical parameters of human's serum. *Am J Drug Alcohol Abuse*. 2010;36:135–139.
57. Fatemi SS, Hasanzadeh M, Arghami A, et al. Lipid profile comparison between opium addicts and non-addicts. *J Tehran Heart Center*. 2008;3:169–172.
58. Lin SH, Yang YK, Lee SY, et al. Association between cholesterol plasma levels and craving among heroin users. *J Addict Med*. 2012;6:287–291.
59. Maccari S, Bassi C, Zanoni P, et al. Plasma cholesterol and triglycerides in heroin addicts. *Drug Alcohol Depend*. 1991;29:183–187.
60. Lehto SM, Hintikka J, Niskanen L, et al. Low HDL cholesterol associates with major depression in a sample with a 7-year history of depressive symptoms. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32:1557–1561.
61. Hibbeln JR, Umhau JC, George DT, et al. Plasma total cholesterol concentrations do not predict cerebrospinal fluid neurotransmitter metabolites: implications for the biophysical role of highly unsaturated fatty acids. *Am J Clin Nutr*. 2000;71(suppl 1):331S–338S.
62. Brown SL, Salive ME, Harris TB, et al. Low cholesterol concentrations and severe depressive symptoms in elderly people. *BMJ*. 1994;308:1328–1332.
63. Zureik M, Courbon D, Ducimetiere P. Serum cholesterol concentration and death from suicide in men: Paris Prospective Study 1. *BMJ*. 1996;313:649–651.
64. McMahon EM, Feldman JM, Schanberg SM. Further studies of methamphetamine-induced insulin release. *Toxicol Appl Pharmacol*. 1975;32:62–72.
65. Karam GA, Reisi M, Kaseb AA, et al. Effects of opium addiction on some serum factors in addicts with non-insulin-dependent diabetes mellitus. *Addict Biol*. 2004;9:53–58.
66. Azod L, Rashidi M, Afkhami-Ardekani M, et al. Effect of opium addiction on diabetes. *Am J Drug Alcohol Abuse*. 2008;34:383–388.

67. Mahani SE, Motamedi F, Ahmadiani A. Involvement of hypothalamic pituitary adrenal axis on the nifedipine-induced antinociception and tolerance in rats. *Pharmacol Biochem Behav.* 2006;85:422–427.
68. Carey M, Gospin R, Goyal A, et al. Opioid receptor activation impairs hypoglycemic counterregulation in humans. *Diabetes.* 2017;66:2764–2773.
69. Escobar M, Scherer JN, Soares CM, et al. Active Brazilian crack cocaine users: nutritional, anthropometric, and drug use profiles. *Rev Bras Psiquiatr.* 2018;40:354–360.
70. Montazerifar F, Karajibani M, Lashkaripour K. Effect of methadone maintenance therapy on anthropometric indices in opioid dependent patients. *Int J High Risk Behav Addict.* 2012;1:100–103.
71. Novick DM, Richman BL, Friedman JM, et al. The medical status of methadone maintenance patients in treatment for 11–18 years. *Drug Alcohol Depend.* 1993;33:235–245.
72. Alves D. Housing and employment situation, body mass index and dietary habits of heroin addicts in methadone maintenance treatment. *Heroin Addict Relat Clin Probl.* 2011;13:1–14.
73. Kheradmand A, Hedayati N, Bannazadeh N, et al. Physical effects of methadone maintenance treatment from the standpoint of clients. *Addict Health.* 2010;2:66–73.
74. Szpanowska-Wohn A, Kolarzyk E, Pach D, et al. Nutritional status of opiate-dependent persons before and during methadone maintenance therapy. *Przeegl Lek.* 2004;61:339–344.
75. Fenn JM, Laurent JS, Sigmon SC. Increases in body mass index following initiation of methadone treatment. *J Subst Abuse Treat.* 2015;51:59–63.
76. Haber PS, Elsayed M, Espinoza D, et al. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. *Drug Alcohol Depend.* 2017;181:132–139.
77. Orsini CA, Ginton G, Shimp KG, et al. Food consumption and weight gain after cessation of chronic amphetamine administration. *Appetite.* 2014;78:76–80.
78. Hodgkins CC, Cahill KS, Seraphine AE, Frostpineda K, et al. Adolescent drug addiction treatment and weight gain. *J Addict Dis.* 2004;23:55–65.
79. Warren CS, Lindsay AR, White EK, et al. Weight-related concerns related to drug use for women in substance abuse treatment: prevalence and relationships with eating pathology. *J Subst Abuse Treat.* 2013;44:494–501.
80. Housova J, Wilczek H, Haluzik MM, et al. Adipocyte-derived hormones in heroin addicts: the influence of methadone maintenance treatment. *Physiol Res.* 2005;54:73–78.
81. Varela P, Marcos A, Ripoll S, et al. Effects of human immunodeficiency virus infection and detoxification time on anthropometric measurements and dietary intake of male drug addicts. *Am J Clin Nutr.* 1997;66:509S–514S.
82. Emerson MH, Glovsky E, Amaro H, et al. Unhealthy weight gain during treatment for alcohol and drug use in four residential programs for Latina and African American women. *Subst Use Misuse.* 2009;44:1553–1565.
83. Collingwood TR, Reynolds R, Kohl HW, et al. Physical fitness effects on substance abuse risk factors and use patterns. *J Drug Educ.* 1991;21:73–84.
84. Sason A, Adelson M, Herzman-Harari S, et al. Knowledge about nutrition, eating habits and weight reduction intervention among methadone maintenance treatment patients. *J Subst Abuse Treat.* 2018;86:52–59.
85. Brecht ML, O'Brien A, von Mayrhauser C, et al. Methamphetamine use behaviors and gender differences. *Addict Behav.* 2004;29:89–106.
86. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. *JAMA.* 1990;264:2511–2518.
87. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry.* 2004;61:807–816.
88. Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. *Arch Gen Psychiatry.* 1997;54:313–321.
89. Tolliver BK, Anton RF. Assessment and treatment of mood disorders in the context of substance abuse. *Dialogues Clin Neurosci.* 2015;17:181–190.
90. Oddy WH, Robinson M, Ambrosini GL, et al. The association between dietary patterns and mental health in early adolescence. *Prev Med.* 2009;49:39–44.
91. Alaimo K, Olson CM, Frongillo EA. Family food insufficiency, but not low family income, is positively associated with dysthymia and suicide symptoms in adolescents. *J Nutr.* 2002;132:719–725.
92. Benton D. The impact of diet on anti-social, violent and criminal behaviour. *Neuroscience Biobehav Rev.* 2007;31:752–774.
93. Silber BY, Schmitt JA. Effects of tryptophan loading on human cognition, mood, and sleep. *Neuroscience Biobehav Rev.* 2010;34:387–407.
94. Steenbergen L, Jongkees BJ, Sellaro R, et al. Tryptophan supplementation modulates social behavior: a review. *Neuroscience Biobehav Rev.* 2016;64:346–358.
95. Parker G, Brotchie H. Mood effects of the amino acids tryptophan and tyrosine. *Acta Psychiatr Scand.* 2011;124:417–426.
96. Jongkees BJ, Hommel B, Kuhn S, et al. Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands: a review. *J Psychiatric Res.* 2015;70:50–57.
97. Chen TJ, Blum K, Payte JT, et al. Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. *Med Hypotheses.* 2004;63:538–548.
98. Herbison CE, Hickling S, Allen KL, et al. Low intake of B-vitamins is associated with poor adolescent mental health and behaviour. *Prev Med.* 2012;55:634–638.
99. Muss C, Mosgoeller W, Endler T. Mood improving potential of a vitamin trace element composition: a randomized, double blind, placebo controlled clinical study with healthy volunteers. *Neuro Endocrinol Lett.* 2016;37:18–28.
100. Młyniec K, Gawel M, Doboszewska U, et al. Essential elements in depression and anxiety. Part II. *Pharmacol Rep.* 2015;67:187–194.
101. Pasco JA, Jacka FN, Williams LJ, et al. Dietary selenium and major depression: a nested case-control study. *Complement Ther Med.* 2012;20:119–123.
102. Almeida OP, Ford AH, Flicker L. Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B12 for depression. *Int Psychogeriatr.* 2015;27:727–737.
103. Garland MR, Hallahan B. Essential fatty acids and their role in conditions characterised by impulsivity. *Int Rev Psychiatry.* 2006;18:99–105.
104. Hallahan B, Garland MR. Essential fatty acids and mental health. *Br J Psychiatry.* 2005;186:275–277.
105. Hibbeln JR, Bissette G, Umhau JC, et al. Omega-3 status and cerebrospinal fluid corticotrophin releasing hormone in perpetrators of domestic violence. *Biol Psychiatry.* 2004;56:895–897.
106. Buydens-Branchey L, Branchey M, Hibbeln JR. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. *Prog Neuropsychopharmacol Biol Psychiatry.* 2008;32:568–575.